A Safety Net That May Not Be So Safe: Elan Sues Biogen Over J&J Deal

Elan's new deal with J&J over its key Alzheimer's assets runs into a brick wall: Biogen.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet